These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2250565)

  • 1. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers.
    Scheinin M; Koulu M; Karhuvaara S; Zimmer RH
    Life Sci; 1990; 47(16):1491-9. PubMed ID: 2250565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
    Scheinin M; Koulu M; Vakkuri O; Vuorinen J; Zimmer RH
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):73-82. PubMed ID: 2300680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
    Dingemanse J; Korn A; Pfefen JP; Güntert TW
    Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
    Holford NH; Guentert TW; Dingemanse J; Banken L
    Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake.
    Juruena MF; Pires ML; Calil HM
    Int Clin Psychopharmacol; 1997 Nov; 12(6):317-21. PubMed ID: 9547133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men.
    Steiger A; Benkert O; Holsboer F
    Neuropsychobiology; 1994; 30(2-3):101-5. PubMed ID: 7800155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
    Bergström M; Westerberg G; Németh G; Traut M; Gross G; Greger G; Müller-Peltzer H; Safer A; Eckernäs SA; Grahnér A; Långström B
    Eur J Clin Pharmacol; 1997; 52(2):121-8. PubMed ID: 9174681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemistry and pharmacology of moclobemide, a prototype RIMA.
    Haefely W; Burkard WP; Cesura AM; Kettler R; Lorez HP; Martin JR; Richards JG; Scherschlicht R; Da Prada M
    Psychopharmacology (Berl); 1992; 106 Suppl():S6-14. PubMed ID: 1546143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers.
    Scheinin M; Karhuvaara S; Ojala-Karlsson P; Kallio A; Koulu M
    Life Sci; 1991; 49(1):75-84. PubMed ID: 1646924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
    Gasic S; Korn A; Eichler HG; Oberhummer I; Zapotoczky HG
    Eur J Clin Pharmacol; 1983; 25(2):173-7. PubMed ID: 6628500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.